Observational studyNaunyn-Schmiedeberg's archives of pharmacology2025
The potential effectiveness of tolvaptan in critically ill patients including cardiac and noncardiac populations: a retrospective observational study.
Observational study in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How to perform fluid de-escalation in critical care.Annals of intensive care · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the potential diuretic effectiveness of the selective arginine vasopressin 2 receptor antagonist tolvaptan in critically ill patients including cardiac and noncardiac populations. This was a single-center retrospective observational study. We analyzed the data of our hospital's critically ill adult patients (n = 473) including noncardiac as well as cardiac populations who had an ICU stay ≥ 4 days in 2019-2020 and who did not undergo renal transplantation or permanent renal replacement therapy before their ICU admission. Adjusting for several confounders (the patients' disease severity, comorbidities including cardiac disease, and diuretics used), we estimated the predictors for the patients whose daily urine volume had increased by up to twofold or more compared to the minimal value (the primary endpoint) by applying a multivariable logistic regression model. We also investigated tolvaptan's effect on time-course changes in the serum creatine (sCr) level (the secondary endpoint) by using a generalized estimating equation model. Tolvaptan use was significantly correlated with increased urine volume (odds ratio [OR] 1.86, 95%CI 1.13-3.06, p = 0.015) but was not significantly associated with time-course changes in the sCr level: beta estimator [95%CI], 0.07 [- 0.01 to 0.15], p = 0.08. Tolvaptan independently increased the urine volume, apparently without worsening the renal function in critically ill patients including cardiac and noncardiac populations.
Indexed as
Identifiers
39556149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.